A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations.

This study is being conducted in Japan.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• Essential hypertension measured by mercury sphygmomanometer

• Outpatients

Exclusion Criteria:

• Secondary hypertension or suspected of having secondary hypertension.

• A history of malignant hypertension

• Severe hypertension

• Significant heart, renal, hepatic diseases or significant cerebrovascular disorder

• Gout Other protocol-defined inclusion/exclusion criteria may apply